Understand the source comparison
Best Peptides for Telomere Maintenance: Mechanism Comparison
Epitalon (AEDG) Direct telomerase activation via TERT upregulation Lengthens telomeres 400–500 bp in 60% of users (6-month human trial data) St. Petersburg Institute trial (n=266); in vitro TRAP assays showing 33–45% activity increase 10 mg total dose over 10
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Epitalon (AEDG)
- Direct telomerase activation via TERT upregulation
- Lengthens telomeres 400–500 bp in 60% of users (6-month human trial data)
- St. Petersburg Institute trial (n=266); in vitro TRAP assays showing 33–45% activity increase
- 10 mg total dose over 10 days, subcutaneous injection
- Only peptide with reproducible human data showing actual telomere elongation—but effects plateau after initial treatment
- Humanin
- STAT3 activation, enhanced antioxidant enzyme expression
- Slows telomere shortening by reducing oxidative damage (no direct elongation)
- Aging Cell 2015 study: fibroblasts maintained longer telomeres over 60 doublings vs controls
- 0.5–2 mg daily, subcutaneous or intranasal
- Works through ROS reduction, not telomerase—best for high-oxidative-stress individuals
- MOTS-c
- Metabolic optimization, mitochondrial efficiency improvement
- Reduces oxidative telomere attrition in metabolically active tissues
- Mouse study: 12% longer muscle telomeres at 18 months; tissue-specific effects
- 5–15 mg 2–3×/week, subcutaneous
- Indirect protection via metabolic pathway—strongest evidence in skeletal muscle and immune cells
- Thymosin alpha-1
- Immune modulation, reduces systemic inflammation (SASP reduction)
- Slows immune cell telomere loss by reducing chronic inflammatory signaling
- Observational: lower telomere attrition rates in thymosin-treated HIV patients vs controls
- 1.6 mg 2×/week, subcutaneous
- Mechanism is plausible but evidence is circumstantial—works if inflammation is the primary driver